Terence Porter, PhD
Over 23 years experience in pharmaceutical and biotechnology industry, with global business development and R&D responsibilities. As Vice President of External Science and Technology at GSK, he co-led negotiations in GSK’s $450 million acquisition of Domantis, the largest GSK technology M&A transaction to date. Previously headed GSK Oncology Licensing worldwide. Licensing experience covers protein-based agents and conventional small molecules across therapeutic areas including oncology, anti-infectives and inflammation, as well as cutting edge science and technology platforms. Core member of a number of senior management committees, including GSK’s most senior R&D scientific review and governance committee for technology platforms and compounds up to clinical proof-of-concept. BSc (Hons) in Biochemistry. Ph.D. in Chemistry from the University of Manchester, UK.
